Patents by Inventor Daniel Scherman

Daniel Scherman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11291630
    Abstract: The present invention relates to gelling compositions, which changes from liquid state to gel state in function of temperature comprising: at least a poloxamer or mixture of poloxamers; at least a gelling agent; and at least an anticancer agent. Said compositions are advantageously used for local administration of an anticancer agent. Said compositions are useful for size-reduction of a tumour before surgical removal of said tumour, for preventing tumour recurrence after surgical removal of a tumour, and/or treating small tumours. They are therefore useful for the treatment of cancer, preferably a cancer of a wall of the digestive system or a gynaecologic cancer. The present invention also relates to a method for preparing said gelling compositions.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: April 5, 2022
    Inventors: Nathalie Mignet, Vincent Pierre-Marie Boudy, Johanne Seguin, Daniel Scherman, Yoran Beldengrun
  • Publication number: 20200368373
    Abstract: The present invention relates to an optical imaging agent of formula (SIGNAL)n-SUPPORT-(L-BIOVECTOR)m, wherein: SUPPORT represents a physiologically acceptable chemical or biological substrate, with a particle size of between 1 and 100 nm, SIGNAL is a fluorophore, L is a linker of formula —C(X)—R1—Y—, with X being O, NH or S R1 being a (C1-C6)alkyl group, optionally R1 being a (C1-C6)alkyl group, optionally interrupted by 1 to 3 groups selected from —O—, —NH—, —C(O)—, —NHC(O)—, —(O)CNH—, —C(O)NH—N?C—, —N?C—, and (I), Y being NH or a —(O)CNH— group, and BIOVECTOR is a carbohydrate targeting markers of inflammation, advantageously selected from the group consisting of mannose, sialyl LewisX and derivatives thereof, n is greater than or equal to 0.5 and is less than 2, m is between 0 and 30, preferably between 1 and 30, more preferably between 5 and 20, diagnostic compositions comprising same and use thereof as a diagnostic agent (in vivo or ex vivo), or as contrast agent for image-guided surgery.
    Type: Application
    Filed: February 21, 2019
    Publication date: November 26, 2020
    Inventors: Yongmin ZHANG, Michel BESSODES, Johanne SEGUIN, Nathalie MIGNET, Daniel SCHERMAN
  • Publication number: 20200291402
    Abstract: The present invention relates to a method for treating a Leber congenital amaurosis in a patient harbouring the mutation c.2991+1655 A>G in the CEP290 gene, comprising the step of administering to said patient at least one antisense oligonucleotide complementary to nucleic acid sequence that is necessary for preventing splicing of the cryptic exon inserted into the mutant c. 2991+1655 A>G CEP290 mRNA.
    Type: Application
    Filed: March 3, 2020
    Publication date: September 17, 2020
    Inventors: Jean-Michel Rozet, Antoine Kichler, Isabelle Perrault, Josseline Kaplan, Xavier Gerard, Daniel Scherman, M. Arnold Munnich
  • Patent number: 10597654
    Abstract: The present invention relates to a method for treating a Leber congenital amaurosis in a patient harbouring the mutation c.2991+1655 A>G in the CEP290 gene, comprising the step of administering to said patient at least one antisense oligonucleotide complementary to nucleic acid sequence that is necessary for preventing splicing of the cryptic exon inserted into the mutant c.2991+1655 A>G CEP290 mRNA.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: March 24, 2020
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), GENETHON, UNIVERSITE PARIS DESCARTES, ENSCP—CHIMIE PARIS TECH—ECOLE NATIONALE SUPERIEURE DE DE CHIME DE PARIS, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS
    Inventors: Jean-Michel Rozet, Antoine Kichler, Isabelle Perrault, Josseline Kaplan, Xavier Gerard, Daniel Scherman, M. Arnold Munnich
  • Publication number: 20190192430
    Abstract: The present invention relates to gelling compositions, which changes from liquid state to gel state in function of temperature comprising: at least a poloxamer or mixture of poloxamers; at least a gelling agent; and at least an anticancer agent. Said compositions are advantageously used for local administration of an anticancer agent. Said compositions are useful for size-reduction of a tumour before surgical removal of said tumour, for preventing tumour recurrence after surgical removal of a tumour, and/or treating small tumours. They are therefore useful for the treatment of cancer, preferably a cancer of a wall of the digestive system or a gynaecologic cancer. The present invention also relates to a method for preparing said gelling compositions.
    Type: Application
    Filed: September 16, 2016
    Publication date: June 27, 2019
    Applicants: Centre National de la Recherche Scientifique (CNRS), Universite Paris Descartes, Assistance Publique-Hopitaux de Paris, Ecole Nationale Superieure de Chimie de Paris, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Nathalie Mignet, Vincent Pierre-Marie Boudy, Johanne Seguin, Daniel Scherman, Yoran Beldengrun
  • Patent number: 9877653
    Abstract: Multimodal optical and magnetic resonance imaging methods based on the use of persistent luminescence nanoparticles. Use of mesoporous persistent luminescence <<core-shell>> complexes for theranostic applications.
    Type: Grant
    Filed: January 30, 2013
    Date of Patent: January 30, 2018
    Assignee: Centre National de la Recherche Scientifique (CNRS)
    Inventors: Thomas Maldiney, Cyrille Richard, Daniel Scherman, Didier Gourier, Bruno Viana, Aurelie Bessiere
  • Publication number: 20180016579
    Abstract: The present invention relates to a method for treating a Leber congenital amaurosis in a patient harbouring the mutation c.2991+1655 A>G in the CEP290 gene, comprising the step of administering to said patient at least one antisense oligonucleotide complementary to nucleic acid sequence that is necessary for preventing splicing of the cryptic exon inserted into the mutant c.
    Type: Application
    Filed: August 31, 2017
    Publication date: January 18, 2018
    Applicants: INSERM (Institut National de la Sante et de la Rec herche Medicale), CNRS (Centre National de la Recherche Scientifique ), GENETHON, UNIVERSITE PARIS DESCARTES, ENSCP - Chimie ParisTech - Ecole Nationale Superie ure de Chimie de Paris, Universite d'Evry-Val-d'Essonne, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
    Inventors: Jean-Michel ROZET, Antoine KICHLER, Isabelle PERRAULT, Josseline KAPLAN, Xavier GERARD, Daniel SCHERMAN, M. Arnold MUNNICH
  • Patent number: 9783547
    Abstract: The present invention relates to 4-azapodophyllotoxin analogs of formula (I) in which X, R1, R2, R3, R4 and Ar are as defined in claim 1, preferably a pharmaceutically acceptable salt thereof, optionally in the form of a solvate, a composition comprising said analogs, their use as medicament, in particular for the treatment of cancer, and a process for their preparation.
    Type: Grant
    Filed: January 15, 2015
    Date of Patent: October 10, 2017
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE PARIS DESCARTES, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ECOLE NATIONALE SUPERIEURE DE CHIMIE DE PARIS
    Inventors: Guy Chabot, Sylviane Giorgi-Renault, Stéphanie Desbene-Finck, Philippe Helissey, Raphaël Labruere, Marlène Testud, Daniel Scherman
  • Patent number: 9777272
    Abstract: The present invention relates to a method for treating a Leber congenital amaurosis in a patient harboring the mutation c.2991+1655 A>G in the CEP290 gene, comprising the step of administering to said patient at least one antisense oligonucleotide complementary to nucleic acid sequence that is necessary for preventing splicing of the cryptic exon inserted into the mutant c.2291+1655 A>G CEP290 mRNA.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: October 3, 2017
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), CNRS (Centre National de la Recherche Scientifique), GENETHON, UNIVERSITE PARIS DESCARTES, ENSCP—Chimie ParisTech—Ecole Nationale Superieure de Chimie de Paris, Universite d'Evry-Val-d'Essonne, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
    Inventors: Jean-Michel Rozet, Antoine Kichler, Isabelle Perrault, Josseline Kaplan, Xavier Gerard, Daniel Scherman, M. Arnold Munnich
  • Patent number: 9572776
    Abstract: The invention relates to a composition including (1) an anionic macromolecule except nucleic acids, (2) a cationic lip, and (3) a nucleic acid having a size lower than or equal to 200 nucleotides, such as an interference RNA, and to the use thereof in gene therapy.
    Type: Grant
    Filed: January 20, 2010
    Date of Patent: February 21, 2017
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE PARIS DESCARTES, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Virginie Escriou, Pascal Bigey, Daniel Scherman
  • Publication number: 20170044533
    Abstract: The present invention relates to a method for treating a Leber congenital amaurosis in a patient harbouring the mutation c.2991+1655 A>G in the CEP290 gene, comprising the step of administering to said patient at least one antisense oligonucleotide complementary to nucleic acid sequence that is necessary for preventing splicing of the cryptic exon inserted into the mutant c.
    Type: Application
    Filed: September 16, 2016
    Publication date: February 16, 2017
    Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), CNRS (Centre National de la Recherche Scientifique), GENETHON, UNIVERSITE PARIS DESCARTES, ENSCP - Chimie ParisTech - Ecole Nationale Superieure de Chimie de Paris, Universite d'Evry-Val-d'Essonne, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
    Inventors: Jean-Michel ROZET, Antoine KICHLER, Isabelle PERRAULT, Josseline KAPLAN, Xavier GERARD, Daniel SCHERMAN, M. Arnold MUNNICH
  • Patent number: 9540425
    Abstract: The present invention relates to specific regions of the N-terminal portion of the VAR2CSA protein and to the use of such specific regions in the prevention of pregnancy-associated malaria. The invention also provides immunogenic compositions and vaccines that are useful for preventing malaria in pregnant women.
    Type: Grant
    Filed: July 29, 2011
    Date of Patent: January 10, 2017
    Assignee: INSTITUT DE RECHERCHE POUR LE DéVELOPPEMENT (IRD)
    Inventors: Nicaise Tuikue Ndam, Philippe Deloron, Sedami Ursula Alix Carine Gnidéhou, Mickaël Quiviger, Pascal Bigey, Daniel Scherman
  • Publication number: 20160333022
    Abstract: The present invention relates to 4-azapodophyllotoxin analogs of formula (I) in which X, R1, R2, R3, R4 and Ar are as defined in claim 1, preferably a pharmaceutically acceptable salt thereof, optionally in the form of a solvate, a composition comprising said analogs, their use as medicament, in particular for the treatment of cancer, and a process for their preparation.
    Type: Application
    Filed: January 15, 2015
    Publication date: November 17, 2016
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE PARIS DESCARTES, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE M EDICALE (INSERM), ECOLE NATIONALE SUPERIEURE DE CHIMIE DE PARIS
    Inventors: Guy CHABOT, Sylviane GIORGI-RENAULT, Stéphanie DESBENE-FINCK, Philippe HELISSEY, Raphaël LABRUERE, Marléne TESTUD, Daniel SCHERMAN
  • Patent number: 9487782
    Abstract: The present invention relates to a method for treating a Leber congenital amaurosis in a patient harboring the mutation c.2991+1655 A>G in the CEP290 gene, comprising the step of administering to said patient at least one antisense oligonucleotide complementary to nucleic acid sequence that is necessary for preventing splicing of the cryptic exon inserted into the mutant c.2291+1655 A>G CEP290 mRNA.
    Type: Grant
    Filed: November 18, 2014
    Date of Patent: November 8, 2016
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), CNRS (Centre National de la Recherche Scientifique), GENETHON, UNIVERSITE PARIS DESCARTES, ENSCP—Chimie ParisTech—Ecole Nationale Superieure de Chimie de Paris, Universite d'Evry-Val-d'Essonne, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
    Inventors: Jean-Michel Rozet, Antoine Kichler, Isabelle Perrault, Josseline Kaplan, Xavier Gerard, Daniel Scherman, M. Arnold Munnich
  • Patent number: 9474782
    Abstract: The invention concerns decorin for increasing muscle mass, particularly in the treatment of muscular dystrophies.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: October 25, 2016
    Assignee: Association Francaise contre les Myopathies
    Inventors: Antoine Kichler, Daniel Scherman
  • Patent number: 9175055
    Abstract: The invention relates to the use of fibromodulin and lumican, particularly active fragments thereof, to increase muscle mass, especially in the treatment of muscular dystrophies.
    Type: Grant
    Filed: October 15, 2012
    Date of Patent: November 3, 2015
    Assignee: ASSOCIATION FRANCAISE CONTRE LES MYOPATHIES
    Inventors: Antoine Kichler, Daniel Scherman
  • Publication number: 20150111951
    Abstract: The present invention relates to a method for treating a Leber congenital amaurosis in a patient harbouring the mutation c.2991+1655 A>G in the CEP290 gene, comprising the step of administering to said patient at least one antisense oligonucleotide complementary to nucleic acid sequence that is necessary for preventing splicing of the cryptic exon inserted into the mutant c.
    Type: Application
    Filed: November 18, 2014
    Publication date: April 23, 2015
    Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), CNRS (Centre National de la Recherche Scientifique), Genethon, Universite Paris Descartes, ENSCP - Chimie ParisTech - Ecole Nationale Superieure de Chimie de Paris, Universite d'Evry-Val-d'Essonne, Assistance Publique Hopitaux De Paris
    Inventors: Jean-Michel ROZET, Antoine KICHLER, Isabelle PERRAULT, Josseline KAPLAN, Xavier GERARD, Daniel SCHERMAN, M. Arnold MUNNICH
  • Patent number: 9012425
    Abstract: The present invention relates to a method for treating a Leber congenital amaurosis in a patient harboring the mutation c.2991+1655 A>G in the CEP290 gene, comprising the step of administering to said patient at least one antisense oligonucleotide complementary to nucleic acid sequence that is necessary for preventing splicing of the cryptic exon inserted into the mutant c.2291+1655 A>G CEP290 mRNA.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: April 21, 2015
    Assignees: INSERM (Institute National de la Sante et de la Recherche Medicale), CNRS (Centre National de la Recherche Scientifique), Genethon, Universite Paris Descartes, ENSCP—Chimie Paris Tech—Ecole National Superieure de Chimie de Paris, Universite d'Evry-Val-d'Essonne, Assistance Publique—Hopitaux de Paris
    Inventors: Jean-Michel Rozet, Antoine Kichler, Isabelle Perrault, Josseline Kaplan, Xavier Gerard, Daniel Scherman, M. Arnold Munnich
  • Publication number: 20140371575
    Abstract: Multimodal optical and magnetic resonance imaging methods based on the use of persistent luminescence nanoparticles. Use of mesoporous persistent luminescence <<core-shell>> complexes for theranostic applications.
    Type: Application
    Filed: January 30, 2013
    Publication date: December 18, 2014
    Inventors: Thomas Maldiney, Cyrille Richard, Daniel Scherman, Didier Gourier, Bruno Viana, Aurelie Bessiere
  • Publication number: 20140323400
    Abstract: The invention relates to the use of fibromodulin and lumican, particularly active fragments thereof, to increase muscle mass, especially in the treatment of muscular dystrophies.
    Type: Application
    Filed: October 15, 2012
    Publication date: October 30, 2014
    Inventors: Antoine Kichler, Daniel Scherman